Entera Bio Ltd. Ordinary Shares
Symbol: ENTX (NASDAQ)
Company Description:
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
- Today's Open: $2.38
- Today's High: $2.545
- Today's Low: $2.256
- Today's Volume: 56.54K
- Yesterday Close: $2.39
- Yesterday High: $2.51
- Yesterday Low: $2.3201
- Yesterday Volume: 42.82K
- Last Min Volume: 50
- Last Min High: $2.315
- Last Min Low: $2.315
- Last Min VWAP: $2.315
- Name: Entera Bio Ltd. Ordinary Shares
- Website: https://www.enterabio.com
- Listed Date: 2018-06-28
- Location: JERUSALEM, L3
- Market Status: Active
- CIK Number: 0001638097
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $109.14M
- Round Lot: 100
- Outstanding Shares: 45.66M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-08 | 10-Q | View |
2025-08-08 | 8-K | View |
2025-07-28 | 8-K | View |
2025-07-18 | 4 | View |
2025-07-18 | 4 | View |
2025-07-18 | 4 | View |
2025-07-18 | 8-K | View |
2025-06-06 | EFFECT | View |
2025-06-06 | 424B3 | View |
2025-06-05 | DEFA14A | View |
2025-06-05 | ARS | View |
2025-06-05 | DEF 14A | View |
2025-06-04 | CORRESP | View |
2025-06-04 | UPLOAD | View |
2025-05-30 | S-8 | View |
2025-05-30 | S-3 | View |
2025-05-23 | UPLOAD | View |
2025-05-20 | 3 | View |
2025-05-20 | CORRESP | View |
2025-05-14 | PRE 14A | View |